VCEL vs VCYT: fair value comparison
Vericel Corporation and Veracyte, Inc. · Updated 2026-10-19
VCEL is still awaiting a full valuation verdict under our six-validated-windows standard. Within Healthcare, VCEL currently ranks higher by quality score.
| VCEL | VCYT | |
|---|---|---|
| Verdict | Awaiting full valuation | Fairly valued |
| Last price | $40.13 | $43.12 |
| 12-month range | $29.34–$48.31 | $30.01–$60.49 |
| Rank by discount to fair value | — | #65 of 108 Healthcare |
| Rank by quality score | #7 of 301 Healthcare | #8 of 301 Healthcare |
| Quality grade | A | A |
| Leverage | Low | Low |
| Margin trend | Expanding | Expanding |
| Revenue growth | Strong | Strong |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Mixed | Mixed |
| 52-week position | The upper-middle quarter | The lower-middle quarter |
Full single-stock breakdowns: VCEL fair value analysis · VCYT fair value analysis